CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 500 filers reported holding CRISPR THERAPEUTICS AG in Q2 2021. The put-call ratio across all filers is 1.18 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $213,332 | -14.7% | 3,800 | -0.8% | 0.01% | -26.7% |
| Q3 2022 | $250,000 | +5.9% | 3,830 | -1.6% | 0.02% | +7.1% |
| Q2 2022 | $236,000 | -0.8% | 3,891 | +2.7% | 0.01% | +27.3% |
| Q1 2022 | $238,000 | -15.3% | 3,787 | +2.3% | 0.01% | -15.4% |
| Q4 2021 | $281,000 | -14.1% | 3,702 | +26.6% | 0.01% | -23.5% |
| Q3 2021 | $327,000 | -18.5% | 2,925 | +18.2% | 0.02% | -19.0% |
| Q2 2021 | $401,000 | +33.2% | 2,474 | +0.3% | 0.02% | +16.7% |
| Q1 2021 | $301,000 | -22.0% | 2,467 | -2.2% | 0.02% | -25.0% |
| Q4 2020 | $386,000 | +83.8% | 2,522 | +0.6% | 0.02% | +60.0% |
| Q3 2020 | $210,000 | – | 2,506 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |